Evidence map›Paper›PMID 28966760›Full record

ArticleChemical science2015

Hyperbranched polydendrons: a new nanomaterials platform with tuneable permeation through model gut epithelium.

Fiona L Hatton, Lee M Tatham, Louise R Tidbury, Pierre Chambon, Tao He, Andrew Owen, Steven P Rannard

Abstract read
In one paragraph

Article in Chemical science, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Fiona L HattonDepartment of Chemistry , University of Liverpool , Crown Street , L69 7ZD , UK . Email: srannard@liv.ac.uk.
Lee M TathamDepartment of Molecular and Clinical Pharmacology , University of Liverpool , Block H, 70 Pembroke Place , Liverpool L69 3GF , UK.
Louise R TidburyDepartment of Molecular and Clinical Pharmacology , University of Liverpool , Block H, 70 Pembroke Place , Liverpool L69 3GF , UK.
Pierre ChambonDepartment of Chemistry , University of Liverpool , Crown Street , L69 7ZD , UK . Email: srannard@liv.ac.uk.
Tao HeInstitute of Chemical and Engineering Sciences , Agency for Science , Technology and Research (ASTAR) , 1, Pesek Road, Jurong Island , 627833 , Singapore.
Andrew OwenDepartment of Molecular and Clinical Pharmacology , University of Liverpool , Block H, 70 Pembroke Place , Liverpool L69 3GF , UK.
Steven P RannardDepartment of Chemistry , University of Liverpool , Crown Street , L69 7ZD , UK . Email: srannard@liv.ac.uk.

Funding

Medical Research Council G0800247
6 · The paper itself

Abstract

The development of nanomaterials for advanced therapies requires the formation of versatile platforms that may be tuned to maximize beneficial attributes and minimize unwanted negative behaviour. Additionally, the optimum route of administration is a key consideration of any new treatment and much work has been focused on direct injection into the systemic circulation rather than oral delivery. Here we describe a new approach to polymeric nanoparticle design and present initial results showing the potential for tuneable permeation through a gut epithelium model. Through the use of mixed initiators and branched vinyl polymerization, a series of systematically varying branched polymers have been synthesized and nanoprecipitated. The surprisingly uniform structures have undergone preliminary pharmacological evaluation to establish low cytotoxicity and enhanced permeation through model intestinal epithelial cells. This presents potential opportunities for future developments that may allow oral dosing to result in circulating polymeric nanoparticles; behaviour that may prove clinically desirable to many non-terminal or chronic diseases that utilise nanomedicines but wish to avoid regular or repeated intravenous administration.

Identifiers

PMID28966760
PMCPMC5586204

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.